Overview

Avelumab in G2-3 NET

Status:
Active, not recruiting

Trial end date:
2021-09-20

Target enrollment:

Participant gender:

Summary

This is a single-center, single-arm, open-label, phase II trial to evaluate the efficacy and safety of avelumab in subjects with unresectable or metastatic, Grade 2-3, well-differentiated neuroendocrine.tumour.

Phase:

Phase 2

Details

Lead Sponsor:

Sunnybrook Health Sciences Centre

Collaborators:

Merck KGaA
Merck KGaA, Darmstadt, Germany

Treatments:

Avelumab